🚀 Zacks Small Cap Research - NSRX: NS002 June KOL Event
🔎 Read the full update:
➡️https://theminingnews.com/zacks-small-cap-research-nsrx-ns002-june-kol-event/
#NasusPhar#NasusPharma0#NSRXS#NS002O#NS003p#KOLx#Anaphylaxisi#Epinephrinea#IntranasalEpinephrineB#EpiPen##Biotecha#BiopharmaT#ClinicalTrials
🔎 Read the full update:
➡️https://theminingnews.com/zacks-small-cap-research-nsrx-ns002-june-kol-event/
#NasusPhar#NasusPharma0#NSRXS#NS002O#NS003p#KOLx#Anaphylaxisi#Epinephrinea#IntranasalEpinephrineB#EpiPen##Biotecha#BiopharmaT#ClinicalTrials
June 23, 2026 at 5:50 AM
🚀 Zacks Small Cap Research - NSRX: NS002 June KOL Event
🔎 Read the full update:
➡️https://theminingnews.com/zacks-small-cap-research-nsrx-ns002-june-kol-event/
#NasusPhar#NasusPharma0#NSRXS#NS002O#NS003p#KOLx#Anaphylaxisi#Epinephrinea#IntranasalEpinephrineB#EpiPen##Biotecha#BiopharmaT#ClinicalTrials
🔎 Read the full update:
➡️https://theminingnews.com/zacks-small-cap-research-nsrx-ns002-june-kol-event/
#NasusPhar#NasusPharma0#NSRXS#NS002O#NS003p#KOLx#Anaphylaxisi#Epinephrinea#IntranasalEpinephrineB#EpiPen##Biotecha#BiopharmaT#ClinicalTrials
🚀 Zacks Small Cap Research - NSRX: First Half 2026 Financial Results
🔎 Read the full update:
➡️https://theminingnews.com/zacks-small-cap-research-nsrx-first-half-2026-financial-results/
#NSRX #Nas#NSRXa#Nasus #ZacksSCR #SmallCap##Biotechn#LifeSciences##PhaseIIS#NS002n#NS003a#E/IntranasalEpinephrine" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#IntranasalEpinephrine
🔎 Read the full update:
➡️https://theminingnews.com/zacks-small-cap-research-nsrx-first-half-2026-financial-results/
#NSRX #Nas#NSRXa#Nasus #ZacksSCR #SmallCap##Biotechn#LifeSciences##PhaseIIS#NS002n#NS003a#E/IntranasalEpinephrine" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#IntranasalEpinephrine
August 21, 2026 at 9:01 PM
🚀 Zacks Small Cap Research - NSRX: First Half 2026 Financial Results
🔎 Read the full update:
➡️https://theminingnews.com/zacks-small-cap-research-nsrx-first-half-2026-financial-results/
#NSRX #Nas#NSRXa#Nasus #ZacksSCR #SmallCap##Biotechn#LifeSciences##PhaseIIS#NS002n#NS003a#E/IntranasalEpinephrine" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#IntranasalEpinephrine
🔎 Read the full update:
➡️https://theminingnews.com/zacks-small-cap-research-nsrx-first-half-2026-financial-results/
#NSRX #Nas#NSRXa#Nasus #ZacksSCR #SmallCap##Biotechn#LifeSciences##PhaseIIS#NS002n#NS003a#E/IntranasalEpinephrine" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#IntranasalEpinephrine
Nasus Pharma posts animal PK & safety study results for intranasal ondansetron (NS003)
*For cancer treatment related nausea & vomiting
*PK profile comparable with IV
*No adverse effects
*Human study in 3Q26
#$NSRX
ir.nasuspharma.com/press_releas...
*For cancer treatment related nausea & vomiting
*PK profile comparable with IV
*No adverse effects
*Human study in 3Q26
#$NSRX
ir.nasuspharma.com/press_releas...
Nasus Pharma Announces Positive Results from Preclinical Pharmacokinetic and Safety Study of Intranasal Ondansetron (NS003) | Nasus Pharma
June 09, 2026 08:00 ETStudy Comparing Intranasal Powder Formulation of Ondansetron Demonstrates Comparable Pharmacokinetic Profile to Intravenous Ondansetro ...
ir.nasuspharma.com
June 9, 2026 at 12:39 PM
Nasus Pharma posts animal PK & safety study results for intranasal ondansetron (NS003)
*For cancer treatment related nausea & vomiting
*PK profile comparable with IV
*No adverse effects
*Human study in 3Q26
#$NSRX
ir.nasuspharma.com/press_releas...
*For cancer treatment related nausea & vomiting
*PK profile comparable with IV
*No adverse effects
*Human study in 3Q26
#$NSRX
ir.nasuspharma.com/press_releas...
#NSRX Nasus Pharma Announces Positive Results from Preclinical Pharmacokinetic and Safety Study of Intranasal Ondansetron (NS003)
https://www.stocktitan.net/news/NSRX/nasus-pharma-announces-positive-results-from-preclinical-vr7vt8uheh5l.html
https://www.stocktitan.net/news/NSRX/nasus-pharma-announces-positive-results-from-preclinical-vr7vt8uheh5l.html
Nasus Pharma Announces Positive Results from Preclinical Pharmacokinetic and Safety Study of Intranasal Ondansetron (NS003)
Nasus Pharma (NYSE:NSRX) reported positive preclinical pharmacokinetic and safety results for NS003, its intranasal powder ondansetron for chemotherapy and post-operative nausea and vomiting.In animal studies, NS003 showed a PK profile comparable to intravenous ondansetron and a favorable safety profile, supporting a planned first-in-human PK study in Q3 2026.
www.stocktitan.net
June 9, 2026 at 12:00 PM
#NSRX Nasus Pharma Announces Positive Results from Preclinical Pharmacokinetic and Safety Study of Intranasal Ondansetron (NS003)
https://www.stocktitan.net/news/NSRX/nasus-pharma-announces-positive-results-from-preclinical-vr7vt8uheh5l.html
https://www.stocktitan.net/news/NSRX/nasus-pharma-announces-positive-results-from-preclinical-vr7vt8uheh5l.html
#NSRX Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update
https://www.stocktitan.net/news/NSRX/nasus-pharma-advances-ns002-towards-pivotal-study-following-positive-y5k3ebnq7wbl.html
https://www.stocktitan.net/news/NSRX/nasus-pharma-advances-ns002-towards-pivotal-study-following-positive-y5k3ebnq7wbl.html
Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update
Nasus Pharma (NYSE: NSRX) reported positive Phase 2 topline results for NS002, showing faster early epinephrine absorption versus EpiPen and consistent absorption under nasal allergic challenge. The company plans a pivotal study to start in Q4 2026 with a planned readout in Q1 2027, and believes results support a potential NDA filing.Nasus is advancing NS003 and NS004 toward first-in-human studies in H2 2026 and is advancing NS005. As of Dec 31, 2025, cash and equivalents were $4.3 million; R&D was $2.4M, G&A $2.7M, and net loss $5.9M. Shares outstanding: 9,015,383.
www.stocktitan.net
March 25, 2026 at 1:00 PM
#NSRX Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update
https://www.stocktitan.net/news/NSRX/nasus-pharma-advances-ns002-towards-pivotal-study-following-positive-y5k3ebnq7wbl.html
https://www.stocktitan.net/news/NSRX/nasus-pharma-advances-ns002-towards-pivotal-study-following-positive-y5k3ebnq7wbl.html
🟢 #$NSRX — Clinical Readout
Positive Preclinical PK and Safety Data - NS003 Intranasal Ondansetron
Preclinical PK and safety study of NS003 (intranasal ondansetron powder) demonstrated a PK profile comparable to IV ondansetron, with similar Tmax and AUC results…
https://biostock.app/symbols/NSRX
Positive Preclinical PK and Safety Data - NS003 Intranasal Ondansetron
Preclinical PK and safety study of NS003 (intranasal ondansetron powder) demonstrated a PK profile comparable to IV ondansetron, with similar Tmax and AUC results…
https://biostock.app/symbols/NSRX
June 9, 2026 at 8:15 PM
🟢 #$NSRX — Clinical Readout
Positive Preclinical PK and Safety Data - NS003 Intranasal Ondansetron
Preclinical PK and safety study of NS003 (intranasal ondansetron powder) demonstrated a PK profile comparable to IV ondansetron, with similar Tmax and AUC results…
https://biostock.app/symbols/NSRX
Positive Preclinical PK and Safety Data - NS003 Intranasal Ondansetron
Preclinical PK and safety study of NS003 (intranasal ondansetron powder) demonstrated a PK profile comparable to IV ondansetron, with similar Tmax and AUC results…
https://biostock.app/symbols/NSRX
